Search Results

The Cepheid Xpert® vanA Assay performed in the GeneXpert® Dx System is a qualitative in vitro diagnostic test designed for rapid detection of the vanA gene sequence associated with vancomycin resistance in bacteria obtained from rectal swab specimens from patients at risk for intestinal colonization with vancomycin-resistant bacteria. The test utilizes automated real-time polymerase chain reaction (PCR) to detect the vanA gene that is frequently associated with vancomycin-resistant enterococci (VRE). The Xpert vanA Assay is intended to aid in the recognition, prevention, and control of vancomycin-resistant organisms that colonize patients in healthcare settings. The Xpert vanA Assay is not intended to diagnose infections caused by vancomycin-resistant bacteria nor to guide or monitor treatment for vancomycin-resistant bacterial infections. Concomitant cultures are necessary to recover organisms for identification of vancomycin-resistant bacteria, antimicrobial susceptibility testing and for epidemiological typing.

The Cepheid Xpert vanA Assay is a rapid, automated in vitro diagnostic test for qualitative detection of the vanA gene sequence associated with vancomycin resistance in bacteria obtained directly from rectal swab specimens. The Xpert vanA Assay system performs real-time multiplex polymerase chain reaction (PCR) for detection of DNA after an initial sample processing step. The assay is performed on the Cepheid GeneXpert® Dx System. The specimen is collected on a double swab, one of which is placed in a tube containing elution reagent. Following brief vortexing, the eluted material and two single-use reagents (Reagent 1 and Reagent 2) that are provided with the assay are transferred to different, uniquely-labeled chambers of the disposable fluidic cartridge (the Xpert vanA cartridge). The user initiates a test from the system user interface and places the cartridge into the GeneXpert® Dx System instrument platform, which performs hands-off realtime, multiplex polymerase chain reaction (PCR) for detection of DNA. In this platform, additional sample preparation, amplification, and real-time detection are all fullyautomated and completely integrated. The GeneXpert® System consists of a GeneXpert instrument, personal computer, and the multi-chambered fluidic cartridges that are designed to complete sample preparation and real-time PCR for detection of the vanA gene that is associated with vancomycin-resistant enterococci (VRE) in less than 45 minutes. Each instrument system has 1 to 16 randomly accessible modules that are each capable of performing separate sample preparation and real-time PCR tests. Each module contains a syringe drive for dispensing fluids, an ultrasonic horn for lysing cells or spores, and a proprietary I-CORE® thermocycler for performing real-time PCR and detection. The Xpert vanA Assay includes reagents for the detection of the vanA resistant gene as well as an internal sample processing control (SPC) to control for adequate processing of the target bacteria and to monitor the presence of inhibitor(s) in the PCR assay. The SPC also ensures the PCR conditions (temperature and time) are appropriate for the amplification reaction and that the PCR reagents are functional. The Probe Check Control (PCC) verifies reagent rehydration, PCR tube filling in the cartridge, probe integrity, and dye stability.

Here's an analysis of the provided text regarding the acceptance criteria and study for the Xpert vanA Assay:

Acceptance Criteria and Device Performance for Xpert vanA Assay

1. Table of Acceptance Criteria and Reported Device Performance

The document does not explicitly state pre-defined acceptance criteria in terms of numerical thresholds for sensitivity, specificity, or agreement. Instead, it demonstrates "substantial equivalence" to predicate devices (a PCR assay and a culture method) and the "current standard of care." The reported performance metrics are presented from clinical comparison studies.

For the purpose of this response, I will interpret the achieved performance relative to the reference standard as the demonstrated effectiveness that led to acceptance.

Note: The document emphasizes that the device is "as safe, as effective, and performs as well as the current standard of care," which implies the stated performance metrics meet the (unspecified) acceptance levels for substantial equivalence.

2. Sample Size Used for the Test Set and Data Provenance

• Sample Size for Test Set: A total of 1231 specimens were tested in the clinical comparison study.
• Data Provenance: The study was a multi-site prospective investigation study conducted at three US institutions.

3. Number of Experts Used to Establish Ground Truth for the Test Set and Their Qualifications

The document does not specify the "number of experts" used in the typical sense of radiologists or other clinicians reviewing images. Instead, the ground truth was established through a multi-step laboratory process:

• Reference Culture: Performed by a central laboratory.
• Bi-directional Sequencing Confirmation: Performed on vancomycin-resistant E. faecalis or E. faecium isolates, sent to a second reference laboratory using alternative vanA specific primers.
• Identification and Susceptibility Testing: Presumptive VRE was definitively identified using the API20S strip (BioMérieux, France) and VRE isolates were tested for susceptibility to glycopeptides using vancomycin E-test strips and agar dilution for teicoplanin.

While specific "expert qualifications" (e.g., years of experience for individual technicians/scientists) are not detailed, the process involves established laboratory protocols and confirmation by multiple methods and reference laboratories, implying a high level of expertise in molecular biology and microbiology.

4. Adjudication Method for the Test Set

The adjudication method was a multi-step laboratory confirmation process, rather than a typical clinical adjudication by multiple human reviewers. The ground truth was established by:

• Reference Culture: Starting with bile esculin azide broth with vancomycin, followed by subculture to agar.
• Presumptive Identification: Gram stain, catalase, and pyr test.
• Definitive Identification: API20S strip.
• Susceptibility Testing: Vancomycin E-test strips and agar dilution for teicoplanin.
• Final Confirmation: Bi-directional sequencing of vanA-positive isolates using independent primers.

This layered approach serves as the "adjudication" to establish the most accurate ground truth for VRE colonization with the vanA gene.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

No, a MRMC comparative effectiveness study was not done.

This device is an in vitro diagnostic (IVD) PCR assay, which produces an objective "Positive" or "Negative" result for the presence of the vanA gene. It does not involve human readers interpreting complex data like medical images, so a study comparing human reader performance with and without AI assistance is not applicable.

6. Standalone Performance Study

Yes, a standalone performance study was done.

The clinical comparison study directly evaluated the Xpert vanA Assay's performance (algorithm only, without human-in-the-loop adjustments to the result) against the established reference culture and bi-directional sequencing gold standard. The reported Percent Positive Agreement, Percent Negative Agreement, Accuracy, PPV, and NPV are all measures of the standalone performance of the device.

7. Type of Ground Truth Used

The ground truth used was a combination of expert consensus laboratory methods:

• Reference culture: Phenotypic detection of vancomycin-resistant enterococci (VRE) growth on selective media.
• Definitive identification and susceptibility testing: Using established laboratory methods (API20S, E-test strips, agar dilution).
• Bi-directional sequencing confirmation: Genetic confirmation of the vanA gene using independent primers.

This provides a robust, multi-faceted ground truth derived from both phenotypic and genotypic characteristics.

8. Sample Size for the Training Set

The document does not specify a sample size for a training set. This is common for IVD assays based on established molecular biology principles (PCR), where the assay design is driven by known genetic targets rather than machine learning on large, annotated datasets requiring separate training and test sets.

The "non-clinical studies" (analytical reactivity, sensitivity, linearity, specificity, interfering substances) describe laboratory-based testing of known strains and samples to characterize the assay's fundamental performance. These experiments might involve optimizing assay parameters, but not in the context of a "training set" for a machine learning algorithm.

For example:

• Analytical Reactivity: Tested 30 vancomycin-resistant enterococci strains and 20 vancomycin-sensitive enterococci strains.
• Analytical Sensitivity (LoD): Used 4 to 10 replicates for estimation and 20 replicates for confirmation.
• Linearity: Used replicates of 4 at each of 6 serial dilutions.
• Analytical Specificity: Tested 42 bacterial and fungal strains.

These are not "training sets" in the AI sense, but rather validation sets for internal development and characterization.

9. How the Ground Truth for the Training Set Was Established

As there is no explicit training set described in the context of a machine learning algorithm, the question of how its ground truth was established is not directly applicable.

The "ground truth" for the analytical studies (e.g., whether a strain is vanA positive or negative, or its CFU/mL concentration) was established by standard microbiological and genetic methods (e.g., strain identification, sequencing, quantitative culturing methods).

Ask a specific question about this device